How to Organize Technical Files for Overseas Registration of Laboratory Equipment?

Key Summary

A professional guide for medical device manufacturers on preparing technical documentation for overseas registration of laboratory equipment, covering regulatory classification, evidence requirements, common pitfalls, and practical checklists.

Key Summary

For overseas registration of laboratory equipment, the first step is to determine whether the product is classified as a medical device, an in-vitro diagnostic device, or a general laboratory instrument in the target country. This regulatory classification dictates the structure of the technical file. Companies should leverage existing NMPA registration dossiers, ISO 13485 quality system documentation, ISO 14971 risk management files, and electrical safety/EMC reports, then supplement with locally required content according to the target country's regulations. Technical files typically include product description, intended use, labels and instructions, risk management, performance verification, software lifecycle, clinical evaluation or exemption justification, sterilization or biocompatibility information, and more.

For multi-country registrations, the core technical file can be reused, but attention must be paid to language requirements, standard versions, test report validity, local authorized representative designations, and post-market surveillance obligations. Common risks include incorrect classification decisions, simple translation without localization, inconsistencies between the technical file and the quality system, and repeated deficiency letters caused by the lack of a local representative. It is advisable to clarify the registration pathway and document checklist early in the project, build the evidence chain systematically, select an experienced local representative, and retain raw data and version records for every report. After approval, companies must also submit change notifications and adverse event reports as required by the target country.

This FAQ article was published on 2026-08-25 and updated on 2026-08-25, based on the AIMEILI registration practice database, international medical device registration knowledge base, and public regulatory information. Specific projects must be assessed against the latest requirements of the target country's regulatory authority and the product's actual documentation.

Applicable Scenarios and Core Questions

Laboratory equipment is a broad category that includes incubators, centrifuges, PCR instruments, microplate readers, biochemical analyzers, mass spectrometers, laboratory water purification systems, and more. Overseas, these devices may fall into different regulatory categories: medical devices, IVD devices, laboratory instruments, or even outside the scope of medical device regulation. The fundamental question is whether the target country treats the product as ordinary laboratory equipment or as a medical device, because that determines the entire direction of technical file preparation.

A common problem is that many companies sell products as "laboratory equipment" domestically, but overseas the same product may be deemed a medical device, requiring compliance with medical device registration rules. For example, PCR instruments used for clinical sample detection and incubators used for patient sample culture are managed as medical devices or IVD devices in many countries. If a company fails to assess the regulatory nature early, the registration pathway can be wrong and the documentation may be rejected.

Core questions include: Does the intended use involve disease diagnosis, treatment, or monitoring? Is it used to process human samples? Does it directly contact human or animal samples? Does it have software functions that influence medical decisions? The answers to these questions directly affect the risk classification and the depth of review required for the technical file.

Registration Determination Logic

Companies should follow a systematic logic to determine the overseas registration pathway, rather than directly applying one country's template.

Step 1: Confirm the target country's regulatory definition. For example, the U.S. FDA classifies laboratory equipment as IVD devices, laboratory equipment, or general-purpose instruments; the EU MDR requires determination based on intended use; GHWP member countries in Southeast Asia, Hong Kong, and the Middle East have their own classification lists. The same product may be classified differently in different countries.

Step 2: Determine the registration pathway based on product risk class. In the U.S., this may be 510(k), De Novo, or PMA; in the EU, classifications range from Class I, IIa, IIb to III; most Southeast Asian countries use risk-based registration or exemption. The risk class also influences clinical evaluation requirements and quality management system audit requirements.

Step 3: Evaluate whether existing registration files can be reused. If the company already holds an NMPA registration certificate, CE mark, FDA submission records, or ISO 13485 certification, these can serve as a foundation. However, every difference from the target country must be checked, including test items, standards, label language, and post-market surveillance obligations.

Step 4: Confirm the local authorized representative. Most countries require a local agent for foreign manufacturers. This representative is responsible for communication with the regulatory authority, receiving deficiency letters, and managing the registration certificate. Without a qualified local agent, many countries will not even accept the registration application.

Documentation and Evidence

Overseas registration technical files generally need to cover the following content:

Product description and intended use;
Labels, instructions, and packaging;
Risk management file;
Product technical requirements and test reports;
Performance verification and evaluation data;
Software research documentation;
Clinical evaluation or exemption justification;
Manufacturing information;
Sterilization or biocompatibility information, if applicable;
Stability and shelf-life verification data.

The document checklist should be prepared according to the target country's requirements. The product description should include model differences, structural composition, working principle, and relationship to similar products. The risk management report must follow ISO 14971 and be consistent with the actual use scenarios. Electrical safety, EMC, and chemical testing reports should come from accredited laboratories, and the report dates must remain within the validity period accepted by the target country.

Performance verification must cover all claimed specifications, including test methods, sample sizes, and statistical results. If the software affects diagnosis or treatment, software lifecycle documentation and cybersecurity evidence must be submitted. Clinical evaluation should cite scientific literature or demonstrate substantial equivalence; it is not acceptable to simply write "not applicable." Labels and instructions must be translated into the target country's language, comply with local regulations, and include manufacturer, representative, warning information, and other required elements.

For multi-country registration in GHWP member states, it is recommended to create a core master document and then add country-specific difference sections. For example, the same risk management, safety test, and performance verification reports can be reused across multiple countries, but standard versions and language requirements must be checked.

Common Mistakes

In practice, companies often make the following errors, leading to deficiency letters and delays:

Incorrect regulatory classification: Filing a medical device as a general laboratory instrument can lead to complete pathway failure.
Simple translation of technical files: Directly translating Chinese documents without considering the regulatory structure and review habits of the target country.
Inconsistent standard versions: Citing domestic or outdated standards instead of updating to standards recognized by the target country.
Perfunctory risk management: Writing a generic risk management report without deep analysis of product functions, misuse scenarios, and clinical risks.
Insufficient performance verification: Small sample sizes, missing statistical justification, or failure to cover major claimed specifications.
Mismatch between labels and actual product: Translations that do not match the test sample or actual product, raising auditor concerns.
Ignoring the local representative: Not confirming the representative's capabilities or facing poor cooperation, resulting in missed response deadlines.
Missing post-market surveillance: Neglecting change notifications, adverse event reporting, and periodic updates after registration is granted.

Enterprise Preparation Checklist

Before starting an overseas registration, companies should prepare the following items:

Target country market research report, including regulatory classification, registration pathway, estimated fees, and timeline.
Product specification sheet and intended use statement.
Quality system certificates, such as ISO 13485, MDSAP, or NMPA system audit records.
Safety test reports, such as IEC 61010, IEC 60601, or target-country designated standards.
Electromagnetic compatibility report.
Performance evaluation reports and specialized test data.
Software lifecycle documentation, including requirements, verification, validation, and post-market monitoring.
Clinical evaluation report or exemption justification.
Product labels, instructions, and packaging files, including translated versions.
Risk management report and risk management plan.
Local representative agreement or authorization document.
Legal documents such as powers of attorney and delegation letters.
Product photos, technical drawings, and process flow charts.
Stability, shelf-life, or transport verification reports.

AIMEILI Perspectives

From the perspective of a regulatory consulting firm, we see many laboratory equipment companies equating "organizing documents" with "translation." This is a major misconception. Overseas registration technical files are not a direct translation of Chinese materials; they are a process of reconstructing the evidence chain. Companies should clearly present the logic that target-country reviewers expect: every safety and effectiveness claim must be supported by corresponding test data, risk analysis, and label descriptions.

The early stage of a project should focus on "regulatory property assessment" and "gap analysis," not immediate translation. We recommend that companies work with an experienced consultant or local representative for the first two weeks to confirm classification, pathway, test item checklist, and the extent to which existing files can be reused. Then, budget and schedule can be set. This phase may seem time-consuming, but it is the most effective way to reduce deficiency risk.

Which documents can be reused? Safety test reports, EMC reports, ISO 14971 risk management framework, raw performance verification data, and software documentation can all form part of the core technical file. However, the following must be localized: classification determination, clinical evaluation justification, label and instruction language and warnings, post-market surveillance plan, and local representative agreement. Do not underestimate the local representative's role, even if it is sometimes treated as a "rubber stamp."

Why are local representatives, certificate control, changes, and renewal so important? Overseas registration certificates are often held by the local applicant or representative. The manufacturer must retain document control and decision-making power. If the representative changes or the certificate is controlled by an uncooperative holder, subsequent change notifications, renewals, and extensions can be blocked. Companies must clarify certificate ownership, data access rights, and change cooperation obligations in the agreement.

How can multi-country registration reduce repetitive work and deficiency risk? We recommend a structure of "core file + country-specific difference files." First, develop a high-quality core file covering risk, performance, software, manufacturing, and label basic framework. Then generate country-specific difference files, such as additional local standard tests, legal requirements, and language versions. This reduces duplication and helps regulators understand the submission.

Common Follow-up Questions

Is clinical evaluation mandatory for laboratory equipment overseas registration?

Not necessarily. If the product is a general laboratory instrument with no medical intended use, clinical evaluation is usually not required. If the product is used for disease diagnosis or to support clinical decisions, clinical evidence is required based on the target country's classification rules. For example, the U.S. FDA may require substantial equivalence for 510(k), while the EU MDR may require clinical trial data or a literature evaluation. Companies should decide through classification queries and regulatory review.

Can the same technical file be used for registration in multiple Southeast Asian countries?

No, not completely identical. Although Southeast Asian countries are GHWP members, their registration regulations, technical document formats, language requirements, and testing standards still differ. Core files can be reused, but local representative information, label language, classification determination, and special testing requirements must be adjusted. For instance, Thailand requires local representative review, Indonesia requires halal compliance certification, and Malaysia accepts English instructions but has some specific detail differences.

How long are test reports in a technical file valid?

There is no uniform validity period. Some countries require that test reports be issued within the last 1 year, while others accept 2 years or longer. Laboratory accreditation must also be recognized by the target country. It is recommended to confirm report validity with the local representative or regulatory authority before submission to avoid rejection due to expired reports.

Need a registration pathway assessment?

Send product type, intended use, target countries and existing certificates. AIMEILI can help evaluate registration pathway, documentation gaps and compliance risks.

Contact AIMEILI